You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis

    SBC: PROTHERA BIOLOGICS, INC.            Topic: NICHD

    Necrotizing enterocolitis (NEC) is a devastating acute inflammatory condition of the gastrointestinal tract resulting in intestinal necrosis, systemic sepsis and multi-system organ failure found mostly in infants born prematurely. Despite modern medical advances in the past decade, the etiology remains elusive and morbidity and mortality are still unacceptably high. It has been concluded that the ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Amino Acids and Pediatric Hepatic Steatosis

    SBC: THE AMINO COMPANY LLC            Topic: 300

    7. Project Summary/Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in North America (1). Hepatic steatosis (HS) is the hallmark of NAFLD (2). NAFLD may transition in sub-groups to chronic inflammation (non- alcoholic steatohepatitis, NASH), and ultimately to cirrhosis. HS is prevalent in all stages of NAFLD. 3-10% of all children in the US and 40-70% of obese ch ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation

    SBC: SAROS THERAPEUTICS INC            Topic: NCI

    Summary Despite the success of immune checkpoint inhibitors for some types of cancer, the overall response rate remains suboptimal. The majority of solid tumors exclude T-cells (termed “cold”), thus presenting a key limiting factor for cancer immunotherapy. Activation of the cGAS-STING pathway has been demonstrated to induce anti-tumor immune responses with impressive efficacy in preclinical s ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Custom Sensor Manufacturing and Regulatory Preparation Assistance for Novel Intraoperative Ureter Detection Device

    SBC: BRITESEED, LLC            Topic: NICHD

    PROJECT SUMMARY/ABSTRACT The goal of this small business innovation research grant is to commercialize a cost-effective and contrast-free intraoperative ureter detection system, which integrates into a laparoscopic vessel sealing device to identify ureters in real-time and prevent iatrogenic injuries. 70% of iatrogenic ureteral injuries are detected postoperatively, up to 30 days after hospital di ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. GEMINI: Virtual Integrative Medical Group Visitsfor Managing Chronic Pain

    SBC: BRIGHTOUTCOME INC.            Topic: NCCIH

    Abstract Chronic pain is associated with substantial suffering and other co-morbidities such as depression, insomnia, fatigue, lowered mobility, and worse quality-of-life. Most of the care of chronic pain patients occurs during hurried primary care visits with pharmacological treatments (e.g. opioids and medications) despite mixed evidence of efficacy and increased risk of potentially dangerous si ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury

    SBC: PROTHERA BIOLOGICS, INC.            Topic: 105

    Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides

    SBC: MIDWEST BIOPROCESSING CENTER LLC            Topic: 300

    Project SummaryThe goal of the proposal presented herein is to produce naturally occurring 6-deoxysugars, including di- and tri-deoxysugars, amino sugars and branched-chain sugars. These specialized hexoses are found as important structural components throughout plant and microbial secondary metabolites, often playing a crucial role in conferring activity in bioactive natural products, such as ant ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Methods for Fast and Efficient Oxygen Imaging

    SBC: O2M TECHNOLOGIES LLC            Topic: 102

    Abstract Intermittent or acute/cyclic hypoxia in tumors, with frequencies between a few cycles per minute to hours, is receiving increased attention because this type of hypoxia has been reported to have an influence on tumor malignancy as well as treatment resistance via increased expression of pro-survival pathways. Fast oxygen imaging methods are needed for the measurement of acute tumor hypoxi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Optimizing NGF for Topical Treatment of Glaucoma

    SBC: HUMAN CELL CO            Topic: NEI

    ABSTRACTGlaucoma is a leading cause of irreversible vision loss, which is characterized by progressive degeneration of retinal ganglion cells (RGC) and their optic nerve axons. While age is a key risk factor, elevated intraocular pressure (IOP) is the only modifiable risk factor, with topical IOP-lowering drugs as the first line treatment. However, RGC degeneration and vision loss continues in hal ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Plans4Care: Personalized Dementia Care On-Demand

    SBC: Plans4Care INC            Topic: R

    PROJECT ABSTRACT Although rt11 million family/friends are caregivers to rt6 million people with Alzheimer's Disease (AD) and AD- Related Dementias (AD/ADRD), they do not typically receive personalized education, strategies and support to manage their own wellbeing and complex dementia-related symptoms. Lack of personalized care contributes to $321 billion annually in AD/ADRD care costs. In respons ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government